Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Shaji Kumar, Surbhi Sidana et al.|Nature Medicine|2023Cited by 239
A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple MyelomaJames R. Berenson, Howard Yeh, Jeffrey Matous et al.|Clinical Cancer Research|2007Cited by 123